Stockscreener 앱 받기
0.5826
6.83%
-0.0427
시간 외 거래:
.62
0.0374
+6.42%
전일 마감가:
$0.6253
열려 있는:
$0.6599
하루 거래량:
123.46K
Relative Volume:
0.35
시가총액:
$51.43M
수익:
-
순이익/손실:
$-23.64M
주가수익비율:
-1.8909
EPS:
-0.3081
순현금흐름:
$-12.89M
1주 성능:
-23.90%
1개월 성능:
-47.51%
6개월 성능:
-67.81%
1년 성능:
-17.94%
1일 변동 폭
$0.5812
$0.6599
1주일 범위
$0.5812
$0.778
52주 변동 폭
$0.5812
$6.19
Citius Oncology Inc Stock (CTOR) Company Profile
명칭
Citius Oncology Inc
전화
(908) 967-6677
주소
11 COMMERCE DRIVE, CRANFORD
Compare CTOR vs TAK, ZTS, HLN, TEVA, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CTOR
Citius Oncology Inc
|
0.5826 | 55.20M | 0 | -23.64M | -12.89M | -0.3081 |
TAK
Takeda Pharmaceutical Co Adr
|
18.04 | 56.42B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
115.93 | 48.64B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.70 | 44.33B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.14 | 33.51B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
531.82 | 22.84B | 3.18B | 1.33B | 1.04B | 27.90 |
Citius Oncology Inc Stock (CTOR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-23 | 업그레이드 | Maxim Group | Hold → Buy |
| 2024-11-27 | 개시 | Maxim Group | Buy |
Citius Oncology Inc 주식(CTOR)의 최신 뉴스
Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR™ in Discussions with Leading Cutaneous Lymphoma Experts - PR Newswire
Citius Oncology (NASDAQ:CTOR) Trading Down 2.8%Here's What Happened - MarketBeat
Citius Oncology (CTOR) expands Lymphir distribution to Europe through exclusive agreement with Uniphar - MSN
If You Invested $1,000 in Citius Pharmaceuticals Inc (CTXR) - Stock Titan
Citius Oncology inks exclusive European distribution pact with Uniphar - MSN
CTXR Stock Price, Quote & Chart | CITIUS PHARMACEUTICALS INC (NASDAQ:CTXR) - ChartMill
Activity Recap: Will Citius Oncology Inc outperform small cap indexes2026 Opening Moves & Safe Entry Trade Reports - baoquankhu1.vn
CTORCitius Oncology, Inc. Latest Stock News & Market Updates - Stock Titan
CTOR Stock Price and Chart — NASDAQ:CTOR - TradingView
Analysts Offer Insights on Healthcare Companies: Citius Oncology (CTOR) and Oruka Therapeutics (ORKA) - The Globe and Mail
Citius Oncology reports positive phase 1 trial data for LYMPHIR By Investing.com - Investing.com Nigeria
Citius Oncology reports positive phase 1 trial data for LYMPHIR - Investing.com Australia
Citius Highlights Positive LYMPHIR Phase 1 Gynecologic Cancer Data - TipRanks
Citius Oncology Reports Positive Phase 1 LYMPHIR Combination Data - TipRanks
Citius reports positive Phase 1 topline: 24% ORR, 48% CBR for LYMPHIR + pembrolizumab in gynecologic cancers - TradingView
Citius Oncology Announces Positive Topline Results from Investig - GuruFocus
Citius Oncology, Inc. Announces Positive Topline Results from Investigator-Initiated Phase 1 Study of Lymphir in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers - marketscreener.com
Citius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers - PR Newswire
Aug EndMonth: Can Citius Oncology Inc lead its sector in growthPortfolio Risk Summary & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
Aug Highlights: Does Citius Oncology Inc have strong fundamentalsMarket Risk Analysis & Weekly Breakout Opportunity Watchlist - baoquankhu1.vn
Citius Pharma (CTXR) Becomes Revenue-Generating With the Commercial Launch of LYMPHIR - Finviz
Citius Oncology reports 86% response rate in lymphoma study By Investing.com - Investing.com Canada
Citius Oncology reports 86% response rate in lymphoma study - Investing.com
Citius Oncology, Inc. announces preliminary topline data from its study in high-risk diffuse large B-cell lymphoma patients - Bitget
Citius Oncology Reports Positive LYMPHIR Phase 1 CAR-T Data - TipRanks
Citius Oncology Announces Positive Phase 1 LYMPHIR Data - TipRanks
Citius Oncology reports 86% ORR and favorable safety for LYMPHIR prior to commercial CAR‑T in high‑risk DLBCL - TradingView
Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR‑T Therapy in High‑Risk Diffuse Large B‑Cell Lymphoma – Company Announcement - Financial Times
Citius Oncology, Inc. (NASDAQ:CTOR) Short Interest Update - MarketBeat
Citius Oncology (CTOR) Expands LYMPHIR Distribution to Europe Through Exclusive Agreement With Uniphar - Finviz
New Jersey tax program turns Citius Pharma losses into $3.8M cash - Stock Titan
CTOR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Market Outlook: Can Citius Oncology Inc keep up with sector leadersJuly 2025 Highlights & High Accuracy Buy Signal Tips - baoquankhu1.vn
Aug Selloffs: What are Merus NVs earnings expectationsMarket Weekly Review & Smart Swing Trading Alerts - baoquankhu1.vn
Aug Drivers: Is TCRT stock showing strong momentumMarket Growth Report & Reliable Price Breakout Signals - baoquankhu1.vn
Is Citius Oncology Inc. stock a contrarian buyTrade Exit Summary & Growth Oriented Trading Recommendations - mfd.ru
Analysts Are Bullish on Top Healthcare Stocks: Citius Oncology (CTOR), Autolus Therapeutics (AUTL) - The Globe and Mail
Aug PreEarnings: Can Citius Oncology Inc lead its sector in growth2025 Breakouts & Breakdowns & Proven Capital Preservation Tips - baoquankhu1.vn
Armistice Capital reports 8.08M Citius Oncology (NASDAQ: CTOR) stake - Stock Titan
Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR - marketscreener.com
Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™ (PR Newswire) - Aktiellt
Citius Oncology expands LYMPHIR access across Europe via exclusive Uniphar deal - Indian Pharma Post
CTOR PE Ratio & Valuation, Is CTOR Overvalued - Intellectia AI
Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR - The Malaysian Reserve
Citius Oncology (NASDAQ:CTOR) Posts Earnings Results, Hits Estimates - MarketBeat
Earnings Breakdown: Citius Oncology Q1 - Benzinga
Citius Oncology Inc (CTOR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.75%
1.88%
자본화:
|
볼륨(24시간):